Paris, France

Jonathan Pol

USPTO Granted Patents = 1 

 

 

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2019

Loading Chart...
Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Contributions of Jonathan Pol

Introduction

Jonathan Pol is a notable inventor based in Paris, France. He has made significant strides in the field of immunology, particularly with his work on vaccine compositions. His innovative approach aims to enhance immune responses in mammals, showcasing his dedication to advancing medical science.

Latest Patents

Jonathan Pol holds a patent for a vaccine composition that describes a kit designed to induce an immune response in a mammal. This kit includes a first virus that expresses various proteins, such as MAGEA3, Human Papilloma Virus E6/E7 fusion protein, and others. The formulation is intended to generate immunity to these proteins in mammals. Additionally, the kit features a Maraba MG1 virus that encodes the same antigen or its variant, which is formulated to effectively induce the immune response. Notably, the first virus is immunologically distinct from the Maraba MG1 virus. This innovative patent highlights his commitment to developing effective immunological solutions.

Career Highlights

Jonathan Pol is associated with Turnstone Limited Partnership, where he continues to contribute to groundbreaking research in vaccine development. His work is characterized by a focus on creating effective immunotherapies that can potentially save lives and improve health outcomes.

Collaborations

Some of his notable coworkers include David F Stojdl and John Cameron Bell, who collaborate with him in advancing their shared goals in immunology and vaccine research.

Conclusion

Jonathan Pol's contributions to the field of immunology through his innovative patent and collaborative efforts underscore his importance as an inventor. His work continues to pave the way for advancements in vaccine technology and immune response therapies.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…